Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Man Group plc

Man Group plc lessened its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 80.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 103,919 shares of the biotechnology company's stock after selling 414,697 shares during the quarter. Man Group plc owned approximately 0.16% of Blueprint Medicines worth $9,064,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BPMC. SG Americas Securities LLC increased its holdings in Blueprint Medicines by 69.7% in the fourth quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company's stock valued at $373,000 after buying an additional 1,756 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Blueprint Medicines by 207.5% during the fourth quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company's stock worth $268,000 after purchasing an additional 2,075 shares during the last quarter. KBC Group NV grew its holdings in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter. R Squared Ltd purchased a new position in shares of Blueprint Medicines during the fourth quarter worth about $51,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Blueprint Medicines by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,470 shares of the biotechnology company's stock worth $1,175,000 after purchasing an additional 1,287 shares during the last quarter.

Insider Activity at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at approximately $6,581,655.32. This trade represents a 3.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ariel Hurley sold 2,752 shares of Blueprint Medicines stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now owns 16,944 shares of the company's stock, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,777 shares of company stock worth $1,256,490 over the last 90 days. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded up $1.16 during mid-day trading on Friday, reaching $101.50. The stock had a trading volume of 353,347 shares, compared to its average volume of 781,410. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm has a market capitalization of $6.56 billion, a price-to-earnings ratio of -93.98 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The business has a 50 day simple moving average of $90.77 and a 200 day simple moving average of $94.63.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The firm had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Blueprint Medicines's revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.40 EPS. On average, analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on BPMC. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. JPMorgan Chase & Co. raised their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Piper Sandler raised their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. JMP Securities reaffirmed a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an "outperform" rating on the stock. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $126.56.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.